
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3508279/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prostate Cancer Screening with Magnetic Resonance Imaging: Results from the Second Round of the Göteborg Prostate Cancer Screening 2 Trial. European Urology Oncology, 2022, 5, 54-60.	5.4	12
2	Prostate Cancer <scp>Diffusionâ€Weighted Magnetic Resonance Imaging</scp> : Does the Choice of <scp>Diffusionâ€Weighting</scp> Level Matter?. Journal of Magnetic Resonance Imaging, 2022, 55, 842-853.	3.4	7
3	The Association Between Age, Prostate Cancer Risk, and Higher Gleason Score in a Long-term Screening Program: Results from the Göteborg-1 Prostate Cancer Screening Trial. European Urology, 2022, 82, 311-317.	1.9	23
4	Lymph swelling after radical prostatectomy and pelvic lymph node dissection. BJU International, 2022, 129, 695-698.	2.5	1
5	Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database. Prostate, 2022, 82, 876-879.	2.3	2
6	Results from 22 years of Followup in the Göteborg Randomized Population-Based Prostate Cancer Screening Trial. Journal of Urology, 2022, 208, 292-300.	0.4	31
7	Risk of severe late toxicity after radiotherapy following radical prostatectomy – a nationwide study. BJU International, 2022, 130, 799-808.	2.5	2
8	Surgeon heterogeneity significantly affects functional and oncological outcomes after radical prostatectomy in the Swedish LAPPRO trial. BJU International, 2021, 127, 361-368.	2.5	24
9	Prostate cancer grading, time to go back to the future. BJU International, 2021, 127, 165-168.	2.5	4
10	Vesicourethral Anastomotic Stenosis After Open or Robot-assisted Laparoscopic Retropubic Prostatectomy—Results from the Laparoscopic Prostatectomy Robot Open Trial. European Urology Focus, 2021, 7, 317-324.	3.1	14
11	The GÖTEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate. Scandinavian Journal of Urology, 2021, 55, 116-124.	1.0	27
12	Impact of cancer screening on metastasis: A prostate cancer case study. Journal of Medical Screening, 2021, 28, 096914132198973.	2.3	0
13	Urinary continence recovery and oncological outcomes after surgery for prostate cancer analysed by risk category: results from the LAParoscopic prostatectomy robot and open trial. World Journal of Urology, 2021, 39, 3239-3249.	2.2	11
14	Bi- or multiparametric MRI in a sequential screening program for prostate cancer with PSA followed by MRI? Results from the GA¶teborg prostate cancer screening 2 trial. European Radiology, 2021, 31, 8692-8702.	4.5	24
15	Association of surgeon and hospital volume with short-term outcomes after robot-assisted radical prostatectomy: Nationwide, population-based study. PLoS ONE, 2021, 16, e0253081.	2.5	10
16	Individual Patient Data Meta-analysis of Discrimination of the Four Kallikrein Panel Associated With the Inclusion of Prostate Volume. Urology, 2021, , .	1.0	1
17	Degree of Preservation of Neurovascular Bundles in Radical Prostatectomy and Recurrence of Prostate Cancer. European Urology Open Science, 2021, 30, 25-33.	0.4	6
18	Hospital readmissions after limited vs. extended lymph node dissection during open and robot-assisted radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 5.e1-5.e8.	1.6	2

#	Article	IF	CITATIONS
19	Is leisure time sitting associated with mortality rates among men diagnosed with localized prostate cancer?. European Journal of Cancer Prevention, 2020, 29, 134-140.	1.3	2
20	Do negative intrusive thoughts at diagnosis predict impaired quality of life, depressed mood and waking up with anxiety 3, 12 and 24 months after radical prostatectomy? – a longitudinal study. Scandinavian Journal of Urology, 2020, 54, 220-226.	1.0	2
21	Risk of Recurrent Disease 6 Years After Open or Robotic-assisted Radical Prostatectomy in the Prospective Controlled Trial LAPPRO. European Urology Open Science, 2020, 20, 54-61.	0.4	7
22	A comparison of side-effects and quality-of-life in patients operated on for prostate cancer with and without salvage radiation therapy. Scandinavian Journal of Urology, 2020, 54, 393-400.	1.0	5
23	Association of Baseline Prostate-Specific Antigen Level With Long-term Diagnosis of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 Years. JAMA Network Open, 2020, 3, e1919284.	5.9	33
24	Populationâ€based, nationwide registration of prostatectomies in Sweden. Journal of Surgical Oncology, 2019, 120, 803-812.	1.7	6
25	Agreement between patient reported outcomes and clinical reports after radical prostatectomy - a prospective longitudinal study. BMC Urology, 2019, 19, 35.	1.4	8
26	The Impact of Design and Performance in Prostate-Specific Antigen Screening: Differences Between ERSPC Centers. European Urology, 2019, 76, 276-279.	1.9	8
27	The value of a bladder-filling protocol for patients with prostate cancer who receive post-operative radiation: results from a prospective clinical trial. Acta Oncológica, 2019, 58, 463-468.	1.8	13
28	Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer?. European Urology, 2019, 75, 1015-1022.	1.9	7
29	90-Day readmission after radical prostatectomy—a prospective comparison between robot-assisted and open surgery. Scandinavian Journal of Urology, 2019, 53, 26-33.	1.0	23
30	Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. European Urology Oncology, 2019, 2, 333-336.	5.4	8
31	Performance and inter-observer variability of prostate MRI (PI-RADS version 2) outside high-volume centres. Scandinavian Journal of Urology, 2019, 53, 304-311.	1.0	31
32	Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres. European Urology Focus, 2019, 5, 186-191.	3.1	3
33	Quality of Life After Open Radical Prostatectomy Compared with Robot-assisted Radical Prostatectomy. European Urology Focus, 2019, 5, 389-398.	3.1	38
34	Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality. Scandinavian Journal of Urology, 2018, 52, 27-37.	1.0	53
35	Social constraints and psychological wellâ€being after prostate cancer: A followâ€up at 12 and 24Âmonths after surgery. Psycho-Oncology, 2018, 27, 668-675.	2.3	7
36	Erectile Function and Oncologic Outcomes Following Open Retropubic and Robot-assisted Radical Prostatectomy: Results from the LAParoscopic Prostatectomy Robot Open Trial. European Urology, 2018, 73, 618-627.	1.9	62

#	Article	IF	CITATIONS
37	The efficacy of prostateâ€specific antigen screening: Impact of key components in the ERSPC and PLCO trials. Cancer, 2018, 124, 1197-1206.	4.1	56
38	Stopping screening, when and how?. Translational Andrology and Urology, 2018, 7, 46-53.	1.4	6
39	Prostate cancer risk assessment in men with an initial P.S.A. below 3 ng/mL: results from the Göteborg randomized population-based prostate cancer screening trial. Scandinavian Journal of Urology, 2018, 52, 256-262.	1.0	9
40	Long-Term Outcomes after Deferred Radical Prostatectomy in Men Initially Treated with Active Surveillance. Journal of Urology, 2018, 200, 779-785.	0.4	11
41	Functional and Oncologic Outcomes Between Open and Robotic Radical Prostatectomy at 24-month Follow-up in the Swedish LAPPRO Trial. European Urology Oncology, 2018, 1, 353-360.	5.4	61
42	Health Economic Analysis of Open and Robot-assisted Laparoscopic Surgery for Prostate Cancer Within the Prospective Multicentre LAPPRO Trial. European Urology, 2018, 74, 816-824.	1.9	58
43	Screening for Prostate Cancer Starting at Age 50–54 Years. A Population-based Cohort Study. European Urology, 2017, 71, 46-52.	1.9	42
44	The drama of prostate cancer diagnostics. Lancet Oncology, The, 2017, 18, e132.	10.7	2
45	Corrigendum re: "Urinary Incontinence and Erectile Dysfunction After Robotic Versus Open Radical Prostatectomy: A Prospective, Controlled, Nonrandomised Trial―[Eur Urol 2015;68:216–25]. European Urology, 2017, 72, e81-e82.	1.9	4
46	How badly did it hit? Self-assessed emotional shock upon prostate cancer diagnosis and psychological well-being: a follow-up at 3, 12, and 24 months after surgery. Acta Oncológica, 2017, 56, 984-990.	1.8	6
47	Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. Annals of Internal Medicine, 2017, 167, 449.	3.9	160
48	Impact of cause of death adjudication on the results of the European prostate cancer screening trial. British Journal of Cancer, 2017, 116, 141-148.	6.4	11
49	Design-corrected variation by centre in mortality reduction in the ERSPC randomised prostate cancer screening trial. Journal of Medical Screening, 2017, 24, 98-103.	2.3	5
50	Oncological and functional outcomes 1 year after radical prostatectomy for veryâ€lowâ€risk prostate cancer: results from the prospective <scp>LAPPRO</scp> trial. BJU International, 2016, 118, 205-212.	2.5	38
51	Preparedness for side effects and bother in symptomatic men after radical prostatectomy in a prospective, non-randomized trial, LAPPRO. Acta Oncológica, 2016, 55, 1467-1476.	1.8	10
52	Psychological Well-being and Private and Professional Psychosocial Support After Prostate Cancer Surgery: A Follow-up at 3, 12, and 24 Months After Surgery. European Urology Focus, 2016, 2, 418-425.	3.1	12
53	Correlation between stage shift and differences in mortality in the European Randomised study of Screening for Prostate Cancer (ERSPC). BJU International, 2016, 118, 677-680.	2.5	9
54	Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis. Cancer, 2016, 122, 3386-3393.	4.1	23

#	Article	IF	CITATIONS
55	Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial. European Urology, 2016, 70, 566-573.	1.9	65
56	Rule-based versus probabilistic selection for active surveillance using three definitions of insignificant prostate cancer. World Journal of Urology, 2016, 34, 253-260.	2.2	11
57	Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening. Clinical Cancer Research, 2016, 22, 243-249.	7.0	35
58	Long-term health-related quality of life after curative treatment for prostate cancer: A regional cross-sectional comparison of two standard treatment modalities. International Journal of Oncology, 2015, 46, 381-388.	3.3	6
59	Active Surveillance for Low-risk Prostate Cancer: Developments to Date. European Urology, 2015, 67, 646-648.	1.9	25
60	Degree of Preservation of the Neurovascular Bundles During Radical Prostatectomy and Urinary Continence 1 Year after Surgery. European Urology, 2015, 67, 559-568.	1.9	107
61	Opportunistic Testing Versus Organized Prostate-specific Antigen Screening: Outcome After 18 Years in the GA¶teborg Randomized Population-based Prostate Cancer Screening Trial. European Urology, 2015, 68, 354-360.	1.9	110
62	Urinary Incontinence and Erectile Dysfunction After Robotic Versus Open Radical Prostatectomy: A Prospective, Controlled, Nonrandomised Trial. European Urology, 2015, 68, 216-225.	1.9	347
63	Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer. European Urology, 2015, 68, 885-890.	1.9	111
64	Short-term Results after Robot-assisted Laparoscopic Radical Prostatectomy Compared to Open Radical Prostatectomy. European Urology, 2015, 67, 660-670.	1.9	84
65	Thromboembolic Complications in 3,544 Patients Undergoing Radical Prostatectomy with or without Lymph Node Dissection. Journal of Urology, 2015, 193, 117-125.	0.4	58
66	Overdetection in screening for prostate cancer. Current Opinion in Urology, 2014, 24, 256-263.	1.8	36
67	RE: Prostate-Specific Antigen Screening Trials and Prostate Cancer Deaths: The Androgen Deprivation Connection. Journal of the National Cancer Institute, 2014, 106, .	6.3	4
68	Rehospitalization after Radical Prostatectomy in a Nationwide, Population Based Study. Journal of Urology, 2014, 192, 112-119.	0.4	25
69	Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet, The, 2014, 384, 2027-2035.	13.7	1,261
70	A Different Method of Evaluation of the ERSPC Trial Confirms That Prostate-specific Antigen Testing Has a Significant Impact on Prostate Cancer Mortality. European Urology, 2014, 66, 401-403.	1.9	14
71	The dilemmas of prostate cancer screening. Medical Journal of Australia, 2013, 198, 528-529.	1.7	4
72	The dilemmas of prostate cancer screening. Medical Journal of Australia, 2013, 199, 583-584.	1.7	0

#	Article	IF	CITATIONS
73	Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: a randomized controlled trial. Journal of Medical Screening, 2013, 20, 33-38.	2.3	8
74	Incidence-based analysis of lethal prostate cancer in Swedish counties with high versus low incidence of prostate cancer in nationwide, population-based registries Journal of Clinical Oncology, 2012, 30, 4668-4668.	1.6	0
75	Radical retropubic prostatectomy: A review of outcomes and side-effects. Acta Oncológica, 2011, 50, 92-97.	1.8	41
76	Prostate Specific Antigen Based Biennial Screening is Sufficient to Detect Almost All Prostate Cancers While Still Curable. Journal of Urology, 2003, 169, 1720-1723.	0.4	45
77	INGUINAL HERNIA AFTER RADICAL RETROPUBIC PROSTATECTOMY FOR PROSTATE CANCER: A STUDY OF INCIDENCE AND RISK FACTORS IN COMPARISON TO NO OPERATION AND LYMPHADENECTOMY. Journal of Urology, 2001, 166, 964-967.	0.4	102
78	Discrimination of Prostate Cancer from Benign Disease by Plasma Measurement of Intact, Free Prostate-specific Antigen Lacking an Internal Cleavage Site at Lys145-Lys146. Clinical Chemistry, 2001, 47, 1415-1423.	3.2	82
79	Screening and early detection of prostate cancer. Prostate, 2000, 44, 255-263.	2.3	27
80	Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam Region). , 1999, 39, 316-322.		88
81	Primary Carcinoid Tumour with Ossification Masquerading as Calyx Stone in a Horseshoe Kidney. Scandinavian Journal of Urology and Nephrology, 1997, 31, 575-578.	1.4	25
82	Diagnosis of Prostate Cancer: Optimal Number of Prostate Biopsies Related to Serum Prostate-specific Antigen and Findings on Digital Rectal Examination. Scandinavian Journal of Urology and Nephrology, 1997, 31, 541-544.	1.4	15
83	Re: Editorial. Journal of Urology, 1996, 156, 1138-1138.	0.4	0
84	Prostate Cancer Mortality in Patients Surviving More Than 10 Years After Diagnosis. Journal of Urology, 1995, 154, 2115-2117.	0.4	40
85	Influence of Benign Prostatic Hyperplasia, Testosterone and age on Serum Levels of Prostate Specific Antigen. Scandinavian Journal of Urology and Nephrology, 1994, 28, 379-384.	1.4	8
86	Outpatient Transurethral Incision of the Prostate Under Local Anesthesia: Operative Results, Patient Security and Cost Effectiveness. Scandinavian Journal of Urology and Nephrology, 1993, 27, 381-385.	1.4	18
87	Crystal Adherence to Rat Bladder Epithelium after Long-Term E. coli Infection. Scandinavian Journal of Urology and Nephrology, 1993, 27, 71-74.	1.4	2
88	Chronic Urinary Tract Infection And Renal Stones. Scandinavian Journal of Urology and Nephrology, 1989, 23, 61-66.	1.4	13
89	Adherence of Urease-Induced Crystals to Rat Bladder Epithelium Following Acute Infection with Different Uropathogenic Microorganisms. Journal of Urology, 1988, 140, 428-430.	0.4	21